These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1324433)

  • 21. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
    Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
    Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
    [No Abstract]   [Full Text] [Related]  

  • 22. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation.
    Hertz MI; Jordan C; Savik SK; Fox JM; Park S; Bolman RM; Dosland-Mullan BM
    J Heart Lung Transplant; 1998 Sep; 17(9):913-20. PubMed ID: 9773865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus infections and liver transplantation: an overview.
    Balfour HH; Heussner RC
    Transplant Proc; 1993 Apr; 25(2):2012-3. PubMed ID: 8385830
    [No Abstract]   [Full Text] [Related]  

  • 24. How effective is oral ganciclovir?
    Martin M; Snydman DR
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):14-5. PubMed ID: 9037271
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
    Puius YA; Snydman DR
    Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy.
    Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Prenner G
    Scand J Infect Dis Suppl; 1995; 99():100-3. PubMed ID: 8668929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CMV infection after kidney transplantation in children.
    Lehnert A; Niaudet P; Broyer M
    Transplant Proc; 1996 Oct; 28(5):2805. PubMed ID: 8908068
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of cytomegalovirus infection after liver transplantation.
    Sampathkumar P; Paya CV
    Liver Transpl; 2000 Mar; 6(2):144-56. PubMed ID: 10719012
    [No Abstract]   [Full Text] [Related]  

  • 31. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation.
    Laske A; Gallino A; Mohacsi P; Bauer EP; Carrel T; von Segesser LK; Turina MI
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1170-3. PubMed ID: 1846456
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients.
    Kelly JL; Albert RK; Wood DE; Raghu G
    Transplantation; 1995 Apr; 59(8):1144-7. PubMed ID: 7732561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A new conception in anti-cytomegalovirus therapy after organ transplantation].
    Shen ZY
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Feb; 21(2):65-6. PubMed ID: 19220950
    [No Abstract]   [Full Text] [Related]  

  • 35. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma of donor-positive/recipient-negative serostatus.
    Avery RK
    Clin Infect Dis; 2007 Aug; 45(4):448-9. PubMed ID: 17638192
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluating sirolimus-based immunosuppression for the prevention of cytomegalovirus replication after liver transplantation.
    Arasaratnam RJ
    Clin Transplant; 2015 Sep; 29(9):723. PubMed ID: 26265556
    [No Abstract]   [Full Text] [Related]  

  • 37. Infection in organ-transplant recipients.
    Fishman JA; Rubin RH
    N Engl J Med; 1998 Jun; 338(24):1741-51. PubMed ID: 9624195
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytomegalovirus and transplantation: yesterday, today, and tomorrow.
    Rubin RH
    Transpl Infect Dis; 1999 Jun; 1(2):87-8. PubMed ID: 11428975
    [No Abstract]   [Full Text] [Related]  

  • 39. Cytomegalovirus infection after transplantation: prevention is still the challenge.
    Reusing Junior JO; David-Neto E
    J Bras Nefrol; 2017; 39(4):353-354. PubMed ID: 29319758
    [No Abstract]   [Full Text] [Related]  

  • 40. Neutralizing activity of immunoglobulin preparations.
    Adler SP
    Transplantation; 2012 Feb; 93(4):e14; author reply e14. PubMed ID: 22314308
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.